Fertility Clinic Regional Hospital Skive
Skive, 7800, Denmark
NCT Number: NCT03725904
The aim of this study is to perform a 12-hour profile of free saliva progesterone during the luteal phase after fresh and frozen embryo transfer. If progesterone levels in saliva samples show a constant level during daytime, this non-invasive measurement can be used in future ART patients with insufficient progesterone levels who might benefit from additional exogenous progesterone supplementation.
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Not applicable
Skive, 7800, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Analysis of salava progesterone
Time frame: 12 hours
Time frame: 8 weeks
Ultrasound detected gestational sack divided with number of embryo transfer
Time frame: 12 weeks
Viable pregnancy after gestational week 12+0
Peter Humaidan
Other
Daytime Profile of Salivary Progesterone During the Mid-luteal Phase of IVF and FET Cycles
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06139757
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Chicago, Illinois, United States
View Trial DetailsNCT03712982
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Waltham, Massachusetts, United States
View Trial DetailsNCT05698550
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Jinan, Shandong, China
View Trial DetailsNCT03349905
Endometriosis, Female Urogenital Diseases
Paris, France
View Trial Details